New brain scan could catch cancer spread earlier, giving patients more treatment options
NCT ID NCT07492121
Summary
This study is testing whether a new MRI contrast agent called gadopiclenol can detect brain metastases earlier than current standard methods. Researchers will enroll 180 patients with advanced lung cancer, breast cancer, or melanoma who are at high risk of cancer spreading to the brain. The goal is to see if earlier detection leads to more treatment options and potentially delays neurological symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital Zurich
Zurich, Canton of Zurich, 8091, Switzerland
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.